TScan Therapeutics Ownership 2024 | Who Owns TScan Therapeutics Now?
Institutional Ownership
43.68%
Insider Ownership
0.88%
Retail Ownership
55.44%
Institutional Holders
78.00
TScan Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 5.51% | 11.08% | 5,224,600 | - | - | 30,563,910 | Jun 30, 2024 |
| ECOR1 CAPITAL, LLC | 5.27% | 0.89% | 5,000,000 | - | - | 29,250,000 | Jun 30, 2024 |
| BLACKROCK INC. | 4.70% | 0.00% | 4,462,352 | 2,763,139 | 162.61% | 26,104,760 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.64% | 0.05% | 4,400,000 | 500,000 | 12.82% | 25,740,000 | Jun 30, 2024 |
| BVF INC/IL | 3.15% | 0.49% | 2,989,474 | - | - | 17,488,423 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 2.94% | 0.21% | 2,784,792 | - | - | 16,291,033 | Jun 30, 2024 |
| VANGUARD GROUP INC | 2.25% | 0.00% | 2,133,613 | 325,461 | 18.00% | 12,481,636 | Jun 30, 2024 |
| PROPEL BIO MANAGEMENT, LLC | 2.20% | 7.92% | 2,087,139 | - | - | 12,209,763 | Jun 30, 2024 |
| DEER MANAGEMENT CO. LLC | 1.31% | 1.50% | 1,245,504 | - | - | 7,286,198 | Jun 30, 2024 |
| ALPHABET INC. | 1.14% | 0.32% | 1,077,080 | - | - | 6,300,918 | Jun 30, 2024 |
| SIMPLIFY ASSET MANAGEMENT INC. | 1.10% | 0.41% | 1,046,916 | - | - | 6,124,459 | Jun 30, 2024 |
| GREAT POINT PARTNERS LLC | 0.99% | 1.05% | 940,831 | 940,831 | 100.00% | 5,503,861 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.95% | 0.00% | 900,499 | 486,720 | 117.63% | 5,269,115 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 0.89% | 1.45% | 845,069 | 845,069 | 100.00% | 4,943,654 | Jun 30, 2024 |
| LMR PARTNERS LLP | 0.70% | 0.03% | 665,529 | 665,529 | 100.00% | 3,893,345 | Jun 30, 2024 |
| DC FUNDS, LP | 0.66% | 61.20% | 630,000 | - | - | 3,685,500 | Jun 30, 2024 |
| STATE STREET CORP | 0.64% | 0.00% | 608,085 | 473,085 | 350.43% | 3,557,297,000 | Jun 30, 2024 |
| INVESCO LTD. | 0.53% | 0.00% | 499,874 | 11,459 | 2.35% | 2,924,263 | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 0.37% | 0.08% | 353,886 | 353,886 | 100.00% | 2,070,233 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.32% | 0.00% | 307,487 | 116,316 | 60.84% | 1,798,798 | Jun 30, 2024 |
TScan Therapeutics's largest institutional shareholder is LYNX1 CAPITAL MANAGEMENT LP, holding 5.51% of the company's total share outstanding, currently valued at $30.56M. The top 10 institutional shareholders own together 33.10% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| DC FUNDS, LP | 0.66% | 61.20% | 630,000 | - | - | 3,685,500 | Jun 30, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 5.51% | 11.08% | 5,224,600 | - | - | 30,563,910 | Jun 30, 2024 |
| PROPEL BIO MANAGEMENT, LLC | 2.20% | 7.92% | 2,087,139 | - | - | 12,209,763 | Jun 30, 2024 |
| DEER MANAGEMENT CO. LLC | 1.31% | 1.50% | 1,245,504 | - | - | 7,286,198 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 0.89% | 1.45% | 845,069 | 845,069 | 100.00% | 4,943,654 | Jun 30, 2024 |
| GREAT POINT PARTNERS LLC | 0.99% | 1.05% | 940,831 | 940,831 | 100.00% | 5,503,861 | Jun 30, 2024 |
| ECOR1 CAPITAL, LLC | 5.27% | 0.89% | 5,000,000 | - | - | 29,250,000 | Jun 30, 2024 |
| BVF INC/IL | 3.15% | 0.49% | 2,989,474 | - | - | 17,488,423 | Jun 30, 2024 |
| SIMPLIFY ASSET MANAGEMENT INC. | 1.10% | 0.41% | 1,046,916 | - | - | 6,124,459 | Jun 30, 2024 |
| ALPHABET INC. | 1.14% | 0.32% | 1,077,080 | - | - | 6,300,918 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 2.94% | 0.21% | 2,784,792 | - | - | 16,291,033 | Jun 30, 2024 |
| DC INVESTMENTS MANAGEMENT, LLC | 0.04% | 0.18% | 35,563 | - | - | 208,044 | Jun 30, 2024 |
| ALPINE GLOBAL MANAGEMENT, LLC | 0.14% | 0.14% | 137,490 | 137,490 | 100.00% | 804,317 | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 0.37% | 0.08% | 353,886 | 353,886 | 100.00% | 2,070,233 | Jun 30, 2024 |
| TROLUCE CAPITAL ADVISORS LLC | 0.10% | 0.05% | 92,832 | 92,832 | 100.00% | 543,067 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.64% | 0.05% | 4,400,000 | 500,000 | 12.82% | 25,740,000 | Jun 30, 2024 |
| LMR PARTNERS LLP | 0.70% | 0.03% | 665,529 | 665,529 | 100.00% | 3,893,345 | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT (UK) LTD | 0.01% | 0.03% | 12,103 | -3,722 | -23.52% | 69,350 | Jun 30, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | 0.02% | 0.02% | 22,940 | 22,940 | 100.00% | 134,199 | Jun 30, 2024 |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | 0.22% | 0.02% | 209,830 | -2,370 | -1.12% | 1,227,506 | Jun 30, 2024 |
The largest TScan Therapeutics shareholder by % of total assets is DC FUNDS, LP. The company owns 630.00K shares of TScan Therapeutics (TCRX), representing 61.20% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BLACKROCK INC. | 4.70% | 0.00% | 4,462,352 | 2,763,139 | 162.61% | 26,104,760 | Jun 30, 2024 |
| GREAT POINT PARTNERS LLC | 0.99% | 1.05% | 940,831 | 940,831 | 100.00% | 5,503,861 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 0.89% | 1.45% | 845,069 | 845,069 | 100.00% | 4,943,654 | Jun 30, 2024 |
| LMR PARTNERS LLP | 0.70% | 0.03% | 665,529 | 665,529 | 100.00% | 3,893,345 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.64% | 0.05% | 4,400,000 | 500,000 | 12.82% | 25,740,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.95% | 0.00% | 900,499 | 486,720 | 117.63% | 5,269,115 | Jun 30, 2024 |
| STATE STREET CORP | 0.64% | 0.00% | 608,085 | 473,085 | 350.43% | 3,557,297,000 | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 0.37% | 0.08% | 353,886 | 353,886 | 100.00% | 2,070,233 | Jun 30, 2024 |
| VANGUARD GROUP INC | 2.25% | 0.00% | 2,133,613 | 325,461 | 18.00% | 12,481,636 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.17% | 0.01% | 163,492 | 163,492 | 100.00% | 956,428 | Jun 30, 2024 |
| ALPINE GLOBAL MANAGEMENT, LLC | 0.14% | 0.14% | 137,490 | 137,490 | 100.00% | 804,317 | Jun 30, 2024 |
| BANK OF MONTREAL /CAN/ | 0.13% | 0.00% | 120,454 | 120,454 | 100.00% | 749,224 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.12% | 0.00% | 116,658 | 116,658 | 100.00% | 682,449 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.32% | 0.00% | 307,487 | 116,316 | 60.84% | 1,798,798 | Jun 30, 2024 |
| TROLUCE CAPITAL ADVISORS LLC | 0.10% | 0.05% | 92,832 | 92,832 | 100.00% | 543,067 | Jun 30, 2024 |
| ABRDN PLC | 0.31% | 0.00% | 292,144 | 92,144 | 46.07% | 1,709,042 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.10% | 0.00% | 90,941 | 90,941 | 100.00% | 532,005 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.12% | 0.00% | 112,941 | 90,837 | 410.95% | 660,705 | Jun 30, 2024 |
| BROWN BROTHERS HARRIMAN & CO | 0.08% | 0.00% | 76,024 | 76,024 | 100.00% | 444,740 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.07% | 0.00% | 69,962 | 69,962 | 100.00% | 409,277 | Jun 30, 2024 |
As of Jun 30 2024, TScan Therapeutics's largest institutional buyer is BLACKROCK INC.. The company purchased 2.76M stocks of TCRX, valued at $26.10M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 0.03% | 0.00% | 27,889 | -364,226 | -92.89% | 163,151 | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 0.06% | 0.00% | 60,400 | -302,084 | -83.34% | 353,340 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.04% | - | 35,268 | -224,880 | -86.44% | 206,318 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.08% | 0.00% | 78,385 | -65,151 | -45.39% | 458,552 | Jun 30, 2024 |
| MAN GROUP PLC | 0.02% | 0.00% | 18,651 | -58,688 | -75.88% | 109,108 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.02% | - | 16,364 | -50,649 | -75.58% | 95,729 | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -44,308 | -100.00% | - | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -41,942 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -37,747 | -100.00% | - | Jun 30, 2024 |
| MARATHON TRADING INVESTMENT MANAGEMENT LLC | 0.01% | 0.01% | 13,600 | -37,400 | -73.33% | 79,560 | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -35,661 | -100.00% | - | Jun 30, 2024 |
| HRT FINANCIAL LP | - | - | - | -34,789 | -100.00% | - | Jun 30, 2024 |
| BREVAN HOWARD CAPITAL MANAGEMENT LP | - | - | - | -34,578 | -100.00% | - | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.04% | 0.01% | 38,300 | -25,000 | -39.49% | 224,055 | Jun 30, 2024 |
| Y-INTERCEPT (HONG KONG) LTD | - | - | - | -24,446 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASIA (SINGAPORE) PTE. LTD. | - | - | - | -19,736 | -100.00% | - | Jun 30, 2024 |
| CANNON GLOBAL INVESTMENT MANAGEMENT, LLC | - | - | - | -17,500 | -100.00% | - | Jun 30, 2024 |
| OMERS ADMINISTRATION CORP | - | - | - | -14,200 | -100.00% | - | Jun 30, 2024 |
| JEFFERIES FINANCIAL GROUP INC. | - | - | - | -12,200 | -100.00% | - | Jun 30, 2024 |
| CTC ALTERNATIVE STRATEGIES, LTD. | - | - | - | -11,000 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, TScan Therapeutics's biggest institutional seller is MILLENNIUM MANAGEMENT LLC. The company sold -0.36M shares of TCRX, valued at $163.15K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| GREAT POINT PARTNERS LLC | 0.99% | 1.05% | 940,831 | 940,831 | 100.00% | 5,503,861 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 0.89% | 1.45% | 845,069 | 845,069 | 100.00% | 4,943,654 | Jun 30, 2024 |
| LMR PARTNERS LLP | 0.70% | 0.03% | 665,529 | 665,529 | 100.00% | 3,893,345 | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 0.37% | 0.08% | 353,886 | 353,886 | 100.00% | 2,070,233 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.17% | 0.01% | 163,492 | 163,492 | 100.00% | 956,428 | Jun 30, 2024 |
| ALPINE GLOBAL MANAGEMENT, LLC | 0.14% | 0.14% | 137,490 | 137,490 | 100.00% | 804,317 | Jun 30, 2024 |
| BANK OF MONTREAL /CAN/ | 0.13% | 0.00% | 120,454 | 120,454 | 100.00% | 749,224 | Jun 30, 2024 |
| TROLUCE CAPITAL ADVISORS LLC | 0.10% | 0.05% | 92,832 | 92,832 | 100.00% | 543,067 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.10% | 0.00% | 90,941 | 90,941 | 100.00% | 532,005 | Jun 30, 2024 |
| BROWN BROTHERS HARRIMAN & CO | 0.08% | 0.00% | 76,024 | 76,024 | 100.00% | 444,740 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.07% | 0.00% | 69,962 | 69,962 | 100.00% | 409,277 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.05% | 0.00% | 46,867 | 46,867 | 100.00% | 274,164 | Jun 30, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | 0.02% | 0.02% | 22,940 | 22,940 | 100.00% | 134,199 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.02% | 0.00% | 20,658 | 20,658 | 100.00% | 121,056 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 0.02% | 0.00% | 20,638 | 20,638 | 100.00% | 120,732 | Jun 30, 2024 |
| NEW YORK STATE COMMON RETIREMENT FUND | 0.02% | 0.00% | 20,093 | 20,093 | 100.00% | 118,000 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | 0.02% | 0.00% | 19,290 | 19,290 | 100.00% | 112,847 | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.02% | 0.00% | 15,383 | 15,383 | 100.00% | 89,991 | Jun 30, 2024 |
| VOYA INVESTMENT MANAGEMENT LLC | 0.01% | 0.00% | 13,603 | 13,603 | 100.00% | 79,578 | Jun 30, 2024 |
| BARCLAYS PLC | 0.01% | - | 13,164 | 13,164 | 100.00% | 77,000 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.01% | 0.00% | 12,245 | 12,245 | 100.00% | 71,634 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.01% | - | 11,882 | 11,882 | 100.00% | 70,475 | Jun 30, 2024 |
| METLIFE INVESTMENT MANAGEMENT, LLC | 0.01% | 0.00% | 10,199 | 10,199 | 100.00% | 59,664 | Jun 30, 2024 |
| LEGAL & GENERAL GROUP PLC | 0.00% | - | 3,937 | 3,937 | 100.00% | 23,012 | Jun 30, 2024 |
| AMERITAS INVESTMENT PARTNERS, INC. | 0.00% | 0.00% | 3,762 | 3,762 | 100.00% | 22,008 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 0.00% | - | 3,611 | 3,611 | 100.00% | 21,000 | Jun 30, 2024 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 0.00% | - | 2,782 | 2,782 | 100.00% | 16,275 | Jun 30, 2024 |
| AMALGAMATED BANK | 0.00% | 0.00% | 1,329 | 1,329 | 100.00% | 8,000 | Jun 30, 2024 |
TScan Therapeutics's largest new institutional shareholder by number of shares is GREAT POINT PARTNERS LLC, purchased 940.83K shares, valued at $5.50M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -44,308 | -100.00% | - | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -41,942 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -37,747 | -100.00% | - | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -35,661 | -100.00% | - | Jun 30, 2024 |
| HRT FINANCIAL LP | - | - | - | -34,789 | -100.00% | - | Jun 30, 2024 |
| BREVAN HOWARD CAPITAL MANAGEMENT LP | - | - | - | -34,578 | -100.00% | - | Jun 30, 2024 |
| Y-INTERCEPT (HONG KONG) LTD | - | - | - | -24,446 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASIA (SINGAPORE) PTE. LTD. | - | - | - | -19,736 | -100.00% | - | Jun 30, 2024 |
| CANNON GLOBAL INVESTMENT MANAGEMENT, LLC | - | - | - | -17,500 | -100.00% | - | Jun 30, 2024 |
| OMERS ADMINISTRATION CORP | - | - | - | -14,200 | -100.00% | - | Jun 30, 2024 |
| JEFFERIES FINANCIAL GROUP INC. | - | - | - | -12,200 | -100.00% | - | Jun 30, 2024 |
| CTC ALTERNATIVE STRATEGIES, LTD. | - | - | - | -11,000 | -100.00% | - | Jun 30, 2024 |
| CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | - | - | - | -10,061 | -100.00% | - | Jun 30, 2024 |
| LAZARD ASSET MANAGEMENT LLC | - | - | - | -2,551 | -100.00% | - | Jun 30, 2024 |
| MACQUARIE GROUP LTD | - | - | - | -1,618 | -100.00% | - | Jun 30, 2024 |
| FEDERATED HERMES, INC. | - | - | - | -56 | -100.00% | - | Jun 30, 2024 |
TScan Therapeutics's largest sold out institutional shareholder by shares sold is CUBIST SYSTEMATIC STRATEGIES, LLC, sold -44.31K shares, valued at -, as of undefined.
TScan Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| BlackRock Health Sciences Trust II | 0.39% | 1,045,767 | - | - | Mar 31, 2024 |
| TEKLA HEALTHCARE INVESTORS | 0.16% | 138,057 | - | - | Mar 31, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.13% | 61,943 | - | - | Mar 31, 2024 |
| BlackRock Health Sciences Trust | 0.12% | 29,940 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.05% | 27,200 | - | - | Mar 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.03% | 63,300 | -25,000 | -28.31% | Mar 28, 2024 |
| Simplify Exchange Traded Funds | 0.02% | 1,046,916 | - | - | Mar 28, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 1,747,918 | -513,402 | -22.70% | Mar 31, 2024 |
| BlackRock ETF Trust | 0.00% | 2,144 | -125 | -5.51% | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 365,160 | 48,906 | 15.46% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 17,329 | -1,791 | -9.37% | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 22,104 | 22,104 | - | Jan 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 29,266 | 10,156 | 53.14% | Feb 29, 2024 |
| THRIVENT SERIES FUND INC | 0.00% | 15,222 | - | - | Mar 28, 2024 |
| BLACKROCK FUNDS | 0.00% | 551,194 | - | - | Mar 28, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 8,117 | 8,117 | - | Jan 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 5,152 | 942 | 22.38% | Jan 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 23,807 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 4,432 | -47 | -1.05% | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 7,166 | - | - | Feb 29, 2024 |
| iSHARES TRUST | 0.00% | 57,207 | -209 | -0.36% | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 712 | 28 | 4.09% | Mar 31, 2024 |
TScan Therapeutics's largest mutual fund holder by % of total assets is "BlackRock Health Sciences Trust II", owning 1.05M shares, compromising 0.39% of its total assets.
TScan Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 78 | 18.18% |
| 31 Mar, 24 | 66 | 22.22% |
| 31 Dec, 23 | 54 | 68.75% |
| 30 Sep, 23 | 32 | 10.34% |
| 30 Jun, 23 | 29 | 3.57% |
| 31 Mar, 23 | 28 | - |
| 31 Dec, 22 | 28 | 12.00% |
| 30 Sep, 22 | 25 | 8.70% |
| 30 Jun, 22 | 23 | -4.17% |
| 31 Mar, 22 | 24 | -14.29% |
| 31 Dec, 21 | 28 | 7.69% |
| 30 Sep, 21 | 26 | - |
As of 30 Jun 24, 78 institutions are holding TScan Therapeutics's shares, representing an increase of 18.18% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 41,438,662 | 20.84% |
| 31 Mar, 24 | 34,293,057 | 7.46% |
| 31 Dec, 23 | 31,912,889 | 11.63% |
| 30 Sep, 23 | 28,588,231 | 2.22% |
| 30 Jun, 23 | 27,967,444 | 189.29% |
| 31 Mar, 23 | 9,667,555 | 1.56% |
| 31 Dec, 22 | 9,519,313 | 0.12% |
| 30 Sep, 22 | 9,508,276 | -1.80% |
| 30 Jun, 22 | 9,682,082 | 2.92% |
| 31 Mar, 22 | 9,407,696 | -4.61% |
| 31 Dec, 21 | 9,861,951 | -2.69% |
| 30 Sep, 21 | 10,134,939 | - |
TScan Therapeutics (TCRX) has 41.44M shares outstanding as of 30 Jun 24, up 20.84% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 43.68% | 1.60% |
| 31 Mar, 24 | 52.28% | 4.62% |
| 31 Dec, 23 | 33.65% | 0.92% |
| 30 Sep, 23 | 60.56% | 0.45% |
| 30 Jun, 23 | 115.44% | 7.25% |
| 31 Mar, 23 | 39.91% | 2.55% |
| 31 Dec, 22 | 39.58% | 2.54% |
| 30 Sep, 22 | 39.50% | 2.44% |
| 30 Jun, 22 | 40.24% | 2.61% |
| 31 Mar, 22 | 39.24% | 1.59% |
| 31 Dec, 21 | 49.62% | 1.91% |
| 30 Sep, 21 | 50.99% | - |
As of 30 Jun 24, TScan Therapeutics is held by 43.68% institutional shareholders, representing a 1.60% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 49 | 25.64% |
| 31 Mar, 24 | 39 | 14.71% |
| 31 Dec, 23 | 34 | 112.50% |
| 30 Sep, 23 | 16 | 14.29% |
| 30 Jun, 23 | 14 | 16.67% |
| 31 Mar, 23 | 12 | - |
| 31 Dec, 22 | 12 | 50.00% |
| 30 Sep, 22 | 8 | -33.33% |
| 30 Jun, 22 | 12 | - |
| 31 Mar, 22 | 12 | - |
| 31 Dec, 21 | 12 | -53.85% |
| 30 Sep, 21 | 26 | - |
49 institutional shareholders have increased their position in TCRX stock as of 30 Jun 24 compared to 39 in the previous quarter (a 25.64% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 13 | 44.44% |
| 31 Mar, 24 | 9 | 80.00% |
| 31 Dec, 23 | 5 | 400.00% |
| 30 Sep, 23 | 1 | -75.00% |
| 30 Jun, 23 | 4 | 33.33% |
| 31 Mar, 23 | 3 | -25.00% |
| 31 Dec, 22 | 4 | -33.33% |
| 30 Sep, 22 | 6 | 100.00% |
| 30 Jun, 22 | 3 | - |
| 31 Mar, 22 | 3 | -50.00% |
| 31 Dec, 21 | 6 | - |
| 30 Sep, 21 | - | - |
13 institutional shareholders have reduced their position in TCRX stock as of 30 Jun 24 compared to 9 in the previous quarter (a 44.44% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 78 | 18.18% | 41,438,662 | 20.84% | 43.68% | 1.60% | 49 | 25.64% | 13 | 44.44% |
| 31 Mar, 24 | 66 | 22.22% | 34,293,057 | 7.46% | 52.28% | 4.62% | 39 | 14.71% | 9 | 80.00% |
| 31 Dec, 23 | 54 | 68.75% | 31,912,889 | 11.63% | 33.65% | 0.92% | 34 | 112.50% | 5 | 400.00% |
| 30 Sep, 23 | 32 | 10.34% | 28,588,231 | 2.22% | 60.56% | 0.45% | 16 | 14.29% | 1 | -75.00% |
| 30 Jun, 23 | 29 | 3.57% | 27,967,444 | 189.29% | 115.44% | 7.25% | 14 | 16.67% | 4 | 33.33% |
| 31 Mar, 23 | 28 | - | 9,667,555 | 1.56% | 39.91% | 2.55% | 12 | - | 3 | -25.00% |
| 31 Dec, 22 | 28 | 12.00% | 9,519,313 | 0.12% | 39.58% | 2.54% | 12 | 50.00% | 4 | -33.33% |
| 30 Sep, 22 | 25 | 8.70% | 9,508,276 | -1.80% | 39.50% | 2.44% | 8 | -33.33% | 6 | 100.00% |
| 30 Jun, 22 | 23 | -4.17% | 9,682,082 | 2.92% | 40.24% | 2.61% | 12 | - | 3 | - |
| 31 Mar, 22 | 24 | -14.29% | 9,407,696 | -4.61% | 39.24% | 1.59% | 12 | - | 3 | -50.00% |
| 31 Dec, 21 | 28 | 7.69% | 9,861,951 | -2.69% | 49.62% | 1.91% | 12 | -53.85% | 6 | - |
| 30 Sep, 21 | 26 | - | 10,134,939 | - | 50.99% | - | 26 | - | - | - |
TScan Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
All Insider Owners Trades
The last insider buy of TCRX was made by BAKER BROS. ADVISORS LP on Apr 23 2024, buying 8,851,451 shares at - per share (worth $885.15).
TScan Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 11 | - | - |
| Q1 2024 | 1 | - | - |
| Q4 2023 | 4 | - | - |
| Q3 2023 | 1 | 4 | 25.00% |
| Q2 2023 | 13 | 4 | 325.00% |
| Q1 2023 | 4 | - | - |
| Q4 2022 | 2 | - | - |
| Q3 2022 | 7 | - | - |
| Q2 2022 | 18 | - | - |
| Q1 2022 | 6 | - | - |
| Q4 2021 | 1 | 1 | 100.00% |
| Q3 2021 | 18 | 20 | 90.00% |
11 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by TScan Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 3 | - | - |
| Q1 2024 | - | - | - |
| Q4 2023 | 3 | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | 1 | 3 | 33.33% |
| Q1 2023 | - | - | - |
| Q4 2022 | 2 | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | 11 | - | - |
| Q1 2022 | 1 | - | - |
| Q4 2021 | - | - | - |
| Q3 2021 | 11 | - | - |
As of Q2 2024, Insider owners conducted 3 open market buy trades and 0 open market sell trades of TScan Therapeutics's stocks.
TScan Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| ARWR | Arrowhead Pharmaceuticals, Inc. |
| CUE | Cue Biopharma, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| VECT | VectivBio Holding AG |
| APLS | Apellis Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PRQR | ProQR Therapeutics N.V. |
| TERN | Terns Pharmaceuticals, Inc. |
| DRMA | Dermata Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ANNX | Annexon, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| ITOS | iTeos Therapeutics, Inc. |
| TFFP | TFF Pharmaceuticals, Inc. |
| CGTX | Cognition Therapeutics, Inc. |
TCRX Ownership FAQ
Who Owns TScan Therapeutics?
TScan Therapeutics is owned by institutional shareholders (43.68%), insiders (0.88%), and public (55.44%). The largest institutional shareholder of TScan Therapeutics is LYNX1 CAPITAL MANAGEMENT LP (5.51% of total shares) and the top mutual fund owner is BlackRock Health Sciences Trust II (0.39% of total shares).
Who are the major institutional shareholders of TScan Therapeutics?
TScan Therapeutics's major institutional shareholders are LYNX1 CAPITAL MANAGEMENT LP, ECOR1 CAPITAL, LLC, BLACKROCK INC., ADAGE CAPITAL PARTNERS GP, L.L.C., and BVF INC/IL. The top five shareholders own together 23.27% of the company's share outstanding.
How many TScan Therapeutics shareholders are there?
As of Jun 2024, there are 78 institutional shareholders of TScan Therapeutics.
What percentage of TScan Therapeutics is owned by LYNX1 CAPITAL MANAGEMENT LP?
LYNX1 CAPITAL MANAGEMENT LP owns 5.22M shares of TScan Therapeutics, representing 5.51% of the company's total shares outstanding, valued at $30.56M (as of Jun 2024).
What percentage of TScan Therapeutics is owned by ECOR1 CAPITAL, LLC?
As of Jun 2024, ECOR1 CAPITAL, LLC holds 5M shares of TScan Therapeutics (TCRX), compromising 5.27% of the company, valued at $29.25M.
What percentage of TScan Therapeutics is owned by BLACKROCK INC?
BLACKROCK INC is the third largest holder of TScan Therapeutics. The company owns 4.46M of the company's shares outstanding (worth $26.1M).